Last reviewed · How we verify
NCT07121335: SABR-OMOP
SMC Radiation Oncology SABR Cohort for Oligometastasis
trial testing Stereotactic body radiotherapy (SBRT) in Stereotactic Body Radiation Therapy (SBRT) in 60 participants. Currently enrolling.
31 December 2027
Quick facts
| Lead sponsor | Samsung Medical Center |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 1 May 2025 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 March 2030 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Stereotactic body radiotherapy (SBRT) — full drug profile →
Conditions studied
- Stereotactic Body Radiation Therapy (SBRT) — all drugs for Stereotactic Body Radiation Therapy (SBRT) →
- Oligometastasis — all drugs for Oligometastasis →
- Oligoprogression — all drugs for Oligoprogression →
- ctDNA — all drugs for ctDNA →
Sponsor
Samsung Medical Center
Who can join
18 and older, any sex, with Stereotactic Body Radiation Therapy (SBRT) or Oligometastasis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to evaluate the efficacy and safety of stereotactic body radiotherapy (SABR) in patients with oligometastatic or oligoprogressive cancer. The main questions it aims to answer are: 1. oncologic outcomes (progression-free survival, local failure rate), 2. patient-reported outcomes, 3. physician-assessed toxicity, and 4. dynamics of circulating tumor DNA (ctDNA) for biomarker analysis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07121335
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Stereotactic body radiotherapy (SBRT)
Trials testing the same drug.
- NCT07456189 — The Efficacy and Safety of Stereotactic Radiotherapy Bridging Allogeneic Hematopoietic Stem Cell Transplantation for the · NA · not yet recruiting
- NCT07145437 — Prostate Stereotactic Radiation and Radio-induced Lymphocyte Apoptosis for Predicting Late Toxicities in Prostate Cancer · NA · not yet recruiting
- NCT07381660 — SBRT Versus Surgical Resection for Small HCC · Phase 3 · not yet recruiting
- NCT07285538 — Stereotactic Body RadioTherapy With Continuous Tracking for Primary and Secondary Renal Cancer · NA · not yet recruiting
- NCT06978296 — HIghly MetAstatic Life Prolonging Therapy-Resistant Prostate Cancer: Role of Stereotactic Radiotherapy for Bone and Lymp · NA · not yet recruiting
Other recruiting trials for Stereotactic Body Radiation Therapy (SBRT)
Currently open trials in the same condition.
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
- NCT06987890 — Practical Geriatric Assessment in Older Adults With Non-Small Cell Lung Cancer Undergoing Stereotactic Body Radiation Th · NA · recruiting
- NCT06738160 — The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy · Phase 2 · recruiting
Other Samsung Medical Center trials
Trials by the same sponsor.
- NCT07482865 — Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support · NA · not yet recruiting
- NCT07467213 — Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute M · Phase 4 · not yet recruiting
- NCT07530913 — Effectiveness Analysis of a Rehabilitation Exercise Platform for Living Donor Liver Transplantation Patients · NA · enrolling by invitation
- NCT07500701 — Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Pro · Phase 3 · recruiting
- NCT07409441 — Korea Acute Myocardial Infarction Registry · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07121335 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Samsung Medical Center
- Last refreshed: 13 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07121335.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing